AZD0530, AN INHIBITOR OF SRC KINASES, IN PLATINUM-PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A TRIAL OF THE PMH PHASE II CONSORTIUM

被引：0
|
作者：
Laurie, Scott A. [1 ]
Goss, Glenwood D. [1 ]
Shepherd, Frances A. [2 ]
Reaume, Neil [1 ]
Nicholas, Garth [1 ]
Philip, Lindsay [2 ]
Wang, Lisa [2 ]
Oza, Amit [2 ]
Hirsh, Vera [3 ]
Wright, James
Leighl, Natasha [2 ]
机构：
[1] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[2] Princess Margaret Hosp, Toronto, ON, Canada
[3] Mcgill Univ Hlth Ctr, Dept Oncol, Montreal, PQ, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
src kinase inhibitor; non-small cell; Phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1262 / S1262
页数：1
相关论文
共 50 条
  • [21] A Prospective Phase II Study of Apatinib Plus Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer
    Ma, K.
    Xu, Y.
    Cai, Y.
    Wang, X.
    Sun, C.
    Guo, Y.
    Qiu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S216 - S217
  • [22] PHASE-II STUDY OF CARBETIMER IN NON-SMALL CELL LUNG-CANCER
    KEATON, M
    BROWN, T
    CRAIG, J
    FRIES, G
    HARMON, G
    ZALOZNIK, A
    ORCZYK, G
    VONHOFF, D
    INVESTIGATIONAL NEW DRUGS, 1990, 8 (04) : 385 - 386
  • [23] Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer
    Gervais, Radj
    Hainsworth, John D.
    Blais, Normand
    Besse, Benjamin
    Laskin, Janessa
    Hamm, John T.
    Lipton, Allan
    Albain, Kathy S.
    Masters, Gregory A.
    Natale, Ronald B.
    Selaru, Paulina
    Kim, Sindy T.
    Chao, Richard C.
    Page, Ray D.
    LUNG CANCER, 2011, 74 (03) : 474 - 480
  • [24] Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
    Spigel, David R.
    Hainsworth, John D.
    Barton, John H.
    Patton, Jeffrey F.
    Zubkus, John D.
    Simons, Lisa
    Griner, Paula
    Burris, Howard A., III
    Greco, F. Anthony
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : 841 - 845
  • [25] Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
    Massuti, Bartomeu
    Cobo, Manuel
    Camps, Carlos
    Domine, Manuel
    Provencio, Mariano
    Alberola, Vicente
    Vinolas, Nuria
    Rosell, Rafael
    Taron, Miguel
    Gutierrez-Calderon, Vanesa
    Lardelli, Pilar
    Alfaro, Vicente
    Nieto, Antonio
    Isla, Dolores
    LUNG CANCER, 2012, 76 (03) : 354 - 361
  • [26] A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer
    Y.-K. Kang
    B.-Y. Ryoo
    T. Y. Kim
    Y.-H. Im
    B.-S. Kim
    Y.-H. Park
    C.-T. Lee
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 518 - 521
  • [27] Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Neubauer, MA
    Garfield, DH
    Kuerfler, PR
    Raju, RN
    Lindquist, DL
    Soo, EW
    Khan, M
    Boehm, KA
    Asmar, L
    LUNG CANCER, 2005, 47 (01) : 121 - 127
  • [28] An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients
    Tredaniel, J.
    Becht, C.
    Bekradda, M.
    De Cremoux, H.
    Alexandre, J.
    Chomy, F.
    Szyldergemajn, S.
    Yataghene, Y.
    Culine, S.
    LUNG CANCER, 2009, 63 (02) : 259 - 263
  • [29] A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer
    Kang, YK
    Ryoo, BY
    Kim, TY
    Im, YH
    Kim, BS
    Park, YH
    Lee, CT
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (06) : 518 - 521
  • [30] Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
    Ho, Cheryl
    Davies, Angela M.
    Sangha, Randeep S.
    Lau, Derick
    Lara, Primo, Jr.
    Chew, Helen K.
    Beckett, Laurel
    Mack, Philip C.
    Riess, Jonathan W.
    Gandara, David R.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1587 - 1591
12345